JP2016014007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016014007A5 JP2016014007A5 JP2015086165A JP2015086165A JP2016014007A5 JP 2016014007 A5 JP2016014007 A5 JP 2016014007A5 JP 2015086165 A JP2015086165 A JP 2015086165A JP 2015086165 A JP2015086165 A JP 2015086165A JP 2016014007 A5 JP2016014007 A5 JP 2016014007A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- group
- isoleucine
- leucine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 23
- -1 tyrosine compound Chemical class 0.000 claims 17
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 11
- 229940024606 amino acid Drugs 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 11
- 229960000310 isoleucine Drugs 0.000 claims 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 4
- 235000013361 beverage Nutrition 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 3
- 102000008934 Muscle Proteins Human genes 0.000 claims 3
- 108010074084 Muscle Proteins Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 238000001243 protein synthesis Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000014616 translation Effects 0.000 claims 3
- 150000003668 tyrosines Chemical class 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 230000003387 muscular Effects 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015086165A JP6496599B2 (ja) | 2014-06-13 | 2015-04-20 | 筋タンパク質合成シグナル活性化剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014122669 | 2014-06-13 | ||
| JP2014122669 | 2014-06-13 | ||
| JP2015086165A JP6496599B2 (ja) | 2014-06-13 | 2015-04-20 | 筋タンパク質合成シグナル活性化剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016014007A JP2016014007A (ja) | 2016-01-28 |
| JP2016014007A5 true JP2016014007A5 (enrdf_load_stackoverflow) | 2018-04-26 |
| JP6496599B2 JP6496599B2 (ja) | 2019-04-03 |
Family
ID=55230521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015086165A Active JP6496599B2 (ja) | 2014-06-13 | 2015-04-20 | 筋タンパク質合成シグナル活性化剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6496599B2 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7008452B2 (ja) | 2017-09-25 | 2022-01-25 | 花王株式会社 | 高吸収型経口チロシン製剤 |
| JP7548014B2 (ja) * | 2018-12-21 | 2024-09-10 | 味の素株式会社 | 筋質向上剤 |
| JP7462127B1 (ja) | 2023-08-16 | 2024-04-05 | 株式会社Healthy Body | 筋肥大用組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2518692B2 (ja) * | 1989-06-14 | 1996-07-24 | 理化学研究所 | 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤 |
| JP4528925B2 (ja) * | 2003-05-30 | 2010-08-25 | 独立行政法人理化学研究所 | アミノ酸組成物及び補液 |
| JP5775657B2 (ja) * | 2006-06-13 | 2015-09-09 | 株式会社明治 | アミノ酸組成物を含有する疲労防止剤 |
| US20100267794A1 (en) * | 2007-10-31 | 2010-10-21 | Meiji Dairies Corporation | Anti-fatigue agent comprising amino acid composition |
| JPWO2010041647A1 (ja) * | 2008-10-06 | 2012-03-08 | 株式会社明治 | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 |
-
2015
- 2015-04-20 JP JP2015086165A patent/JP6496599B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4501932A3 (en) | Kras g12c inhibitors | |
| EP4512399A3 (en) | Solid state forms of tafamidis and salts thereof | |
| WO2018175258A8 (en) | Methods and compositions for preparing nucleic acid libraries | |
| MX2017011974A (es) | Estabilizacion del 1-cloro-3,3,3-trifluoropropeno. | |
| HK1251466A1 (zh) | 包含pi3k抑制剂和hdac抑制剂的组合物 | |
| WO2016094702A3 (en) | Methods for modulating taste receptors | |
| WO2018224689A3 (en) | SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | |
| EP4327880A3 (en) | Solid state form of ribociclib succinate | |
| MX2018001205A (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h. | |
| NZ745210A (en) | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor | |
| GB2585414B (en) | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen | |
| MY202765A (en) | Triesters of cyclohexanetripropionic acid | |
| PH12020500074A1 (en) | Peptide | |
| PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| JP2016014007A5 (enrdf_load_stackoverflow) | ||
| PH12017501444A1 (en) | (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| UA94716C2 (ru) | Кальциепептидный компонент для снижения веса тела | |
| WO2016076607A3 (ko) | Compound k 성분이 강화된 홍삼농축액을 함유하는 비알코올성 지방간증의 예방 및 치료용 약제학적 조성물 및 건강기능 식품 | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| JP2016160183A5 (ja) | 筋萎縮抑制剤及び筋萎縮抑制用飲食品 | |
| PH12018500433B1 (en) | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | |
| WO2016189385A3 (en) | Enhanced salt compositions and methods of preparation thereof | |
| JP2014201572A5 (enrdf_load_stackoverflow) | ||
| WO2012126686A3 (en) | Saffron odorants |